New Asthma injection offers fresh hope for severe asthma suffers.

Posted on September 9, 2016
Archive : September 2016
Category : News

Benralizumab injections reduce exacerbations in severe, uncontrolled asthma, according to two trials

The two trials, published in The Lancet and presented at the European Respiratory Society meeting in London, looked at the safety and efficacy of benralizumab as an add-on therapy for patients with severe, uncontrolled asthma -- a group of patients who have few treatment options available and high rates of hospitalisation.

Asthma affects an estimated 315 million people worldwide, approximately 10% of whom have severe or uncontrolled asthma. Patients with severe asthma require treatment with high-dose inhaled corticosteroids (ISC) and long-acting beta agonists (LABA) to control the illness -- both are delivered in the form of inhalers. However, for some patients, current treatments fail to control their asthma and they remain at high risk of exacerbations and hospitalisation.

"The results from both trials indicate that benralizumab treatment once every 4 or 8 weeks decreased eosinophil counts, reduced asthma exacerbations, and improved lung function for patients with severe, uncontrolled asthma with eosinophilia" adds Professor J. Mark FitzGerald, The Lung Centre, Vancouver Coastal Health, University of British Columbia, Vancouver, BC, Canada, lead author of the CALIMA trial. "Additional therapeutic options to control severe asthma are urgently needed and our findings support the use of benralizumab as an add-on therapy for the treatment of severe asthma with persistent eosinophilia."

Read the full article here:  Science Daily